Literature DB >> 15533763

Leishmaniasis: drugs in the clinic, resistance and new developments.

Marc Ouellette1, Jolyne Drummelsmith, Barbara Papadopoulou.   

Abstract

The control of Leishmania infections relies primarily on chemotherapy. The arsenal of drugs available for treating Leishmania infections is limited and includes pentavalent antimonials, pentamidine, amphotericin B, miltefosine, fluconazole and few other drugs at various stages of their development process. In this review, we will discuss the latest results regarding resistance mechanisms to drugs used in the clinic against Leishmania infections.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15533763     DOI： 10.1016/j.drup.2004.07.002

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN： 1368-7646            Impact factor:   18.500


  93 in total

1.  In silico work flow for scaffold hopping in Leishmania.

Authors:  Barnali Waugh; Ambarnil Ghosh; Dhananjay Bhattacharyya; Nanda Ghoshal; Rahul Banerjee
Journal:  BMC Res Notes       Date:  2014-11-17

2.  Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani.

Authors:  Dhiraj Kumar; Ruchi Singh; Vasundhra Bhandari; Arpita Kulshrestha; Narendra Singh Negi; Poonam Salotra
Journal:  Parasitol Res       Date:  2012-07       Impact factor: 2.289

3.  Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance.

Authors:  Mansi Garg; Shyam Sundar; Robert Duncan; Hira L Nakhasi; Neena Goyal
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

4.  Leishmania tarentolae: purification and characterization of tubulin and its suitability for antileishmanial drug screening.

Authors:  Adam J Yakovich; Frank L Ragone; Juan D Alfonzo; Dan L Sackett; Karl A Werbovetz
Journal:  Exp Parasitol       Date:  2006-06-05       Impact factor: 2.011

5.  Intracellular localization of the ABCC proteins of Leishmania and their role in resistance to antimonials.

Authors:  Philippe Leprohon; Danielle Légaré; Marc Ouellette
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

6.  Chronic arsenic exposure and microbial drug resistance.

Authors:  Malcolm J McConville; Stuart A Ralph
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-13       Impact factor: 11.205

7.  Cos-Seq for high-throughput identification of drug target and resistance mechanisms in the protozoan parasite Leishmania.

Authors:  Élodie Gazanion; Christopher Fernández-Prada; Barbara Papadopoulou; Philippe Leprohon; Marc Ouellette
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

Review 8.  Phospholipid and sphingolipid metabolism in Leishmania.

Authors:  Kai Zhang; Stephen M Beverley
Journal:  Mol Biochem Parasitol       Date:  2009-12-23       Impact factor: 1.759

9.  Fatty acid profiles in Leishmania spp. isolates with natural resistance to nitric oxide and trivalent antimony.

Authors:  Alana Freire de Azevedo; Jorge Luís de Lisboa Dutra; Micheli Luize Barbosa Santos; Darlisson de Alexandria Santos; Péricles Barreto Alves; Tatiana Rodrigues de Moura; Roque Pacheco de Almeida; Marcelo Ferreira Fernandes; Ricardo Scher; Roberta Pereira Miranda Fernandes
Journal:  Parasitol Res       Date:  2013-10-06       Impact factor: 2.289

10.  A new ABC half-transporter in Leishmania major is involved in resistance to antimony.

Authors:  J I Manzano; R García-Hernández; S Castanys; F Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.